Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stefan Walzer

Showing results (31-40 of 46) with videos related to

Pageof 5
Sort By:
Current Medical Research and Opinion|October 6, 2011
An indirect comparison of the efficacy of bevacizumab plus carboplatin and paclitaxel versus pemetrexed with cisplatin in patients with advanced or recurrent non-squamous adenocarcinoma non-small cell lung cancerMark J C Nuijten, Rick Aultman, Javier de Castro Carpeño, et al.
Clinical Nutrition (Edinburgh, Scotland)|March 10, 2020
Economic evaluation of individualized nutritional support in medical inpatients: Secondary analysis of the EFFORT trialPhilipp Schuetz, Suela Sulo, Stefan Walzer, et al.
BMJ Open|July 10, 2021
Cost savings associated with nutritional support in medical inpatients: an economic model based on data from a systematic review of randomised trialsPhilipp Schuetz, Suela Sulo, Stefan Walzer, et al.
Lung Cancer (Amsterdam, Netherlands)|December 14, 2011
A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancerMark J C Nuijten, Javier de Castro Carpeño, Christos Chouaid, et al.
Diabetes Technology & Therapeutics|June 1, 2006
Development and validation of the Economic Assessment of Glycemic Control and Long-Term Effects of diabetes (EAGLE) modelElvira Mueller, Stefanie Maxion-Bergemann, Dmitry Gultyaev, et al.
Lung Cancer (Amsterdam, Netherlands)|May 20, 2011
Comparison of treatment costs of grade 3/4 adverse events associated with erlotinib or pemetrexed maintenance therapy for patients with advanced non-small-cell lung cancer (NSCLC) in Germany, France, Italy, and SpainKurt Banz, Helge Bischoff, Matthias Brunner, et al.
Brain and Behavior|November 6, 2025
Epidemiology of Parkinson's Disease in Germany Between 2016 and 2021 Based on Statutory Health Insurance Claims DataDirk Woitalla, Gisa Ellrichmann, Stefan Jun Groiss, et al.
Lung Cancer (Amsterdam, Netherlands)|August 24, 2010
Societal cost savings through bevacizumab-based treatment in non-small cell lung cancer (NSCLC)Sanja Stanisic, Helge G Bischoff, David F Heigener, et al.
Lung Cancer (Amsterdam, Netherlands)|August 24, 2010
Effectiveness of bevacizumab- and pemetrexed-cisplatin treatment for patients with advanced non-squamous non-small cell lung cancerMark Nuijten, David F Heigener, Helge G Bischoff, et al.
Clinicoeconomics and Outcomes Research : CEOR|October 3, 2012
Maintenance erlotinib in advanced nonsmall cell lung cancer: cost-effectiveness in EGFR wild-type across EuropeSilke Walleser, Joshua Ray, Helge Bischoff, et al.
Pageof 5

Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
Current Medical Research and Opinion|October 6, 2011
An indirect comparison of the efficacy of bevacizumab plus carboplatin and paclitaxel versus pemetrexed with cisplatin in patients with advanced or recurrent non-squamous adenocarcinoma non-small cell lung cancerMark J C Nuijten, Rick Aultman, Javier de Castro Carpeño, et al.
Clinical Nutrition (Edinburgh, Scotland)|March 10, 2020
Economic evaluation of individualized nutritional support in medical inpatients: Secondary analysis of the EFFORT trialPhilipp Schuetz, Suela Sulo, Stefan Walzer, et al.
BMJ Open|July 10, 2021
Cost savings associated with nutritional support in medical inpatients: an economic model based on data from a systematic review of randomised trialsPhilipp Schuetz, Suela Sulo, Stefan Walzer, et al.
Lung Cancer (Amsterdam, Netherlands)|December 14, 2011
A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancerMark J C Nuijten, Javier de Castro Carpeño, Christos Chouaid, et al.
Diabetes Technology & Therapeutics|June 1, 2006
Development and validation of the Economic Assessment of Glycemic Control and Long-Term Effects of diabetes (EAGLE) modelElvira Mueller, Stefanie Maxion-Bergemann, Dmitry Gultyaev, et al.
Lung Cancer (Amsterdam, Netherlands)|May 20, 2011
Comparison of treatment costs of grade 3/4 adverse events associated with erlotinib or pemetrexed maintenance therapy for patients with advanced non-small-cell lung cancer (NSCLC) in Germany, France, Italy, and SpainKurt Banz, Helge Bischoff, Matthias Brunner, et al.
Brain and Behavior|November 6, 2025
Epidemiology of Parkinson's Disease in Germany Between 2016 and 2021 Based on Statutory Health Insurance Claims DataDirk Woitalla, Gisa Ellrichmann, Stefan Jun Groiss, et al.
Lung Cancer (Amsterdam, Netherlands)|August 24, 2010
Societal cost savings through bevacizumab-based treatment in non-small cell lung cancer (NSCLC)Sanja Stanisic, Helge G Bischoff, David F Heigener, et al.
Lung Cancer (Amsterdam, Netherlands)|August 24, 2010
Effectiveness of bevacizumab- and pemetrexed-cisplatin treatment for patients with advanced non-squamous non-small cell lung cancerMark Nuijten, David F Heigener, Helge G Bischoff, et al.
Clinicoeconomics and Outcomes Research : CEOR|October 3, 2012
Maintenance erlotinib in advanced nonsmall cell lung cancer: cost-effectiveness in EGFR wild-type across EuropeSilke Walleser, Joshua Ray, Helge Bischoff, et al.
Pageof 5